Ads
related to: drospirenone and ethinyl estradiol 3 mg/0.02mg- NEXTSTELLIS® Efficacy
Visit HCP Site for Safety &
Efficacy Info on NEXTSTELLIS®.
- NEXTSTELLIS® Safety
Visit HCP Site for the Long-Term
Safety Profile of NEXTSTELLIS®.
- Dosing & Prescribing
Learn More About Starting
Your Patients on NEXTSTELLIS®.
- Why NEXTSTELLIS®
Learn More About NEXTSTELLIS®
& Its Tolerability. Visit HCP Site.
- NEXTSTELLIS® Efficacy
Search results
Results from the WOW.Com Content Network
The medication is taken by mouth and contains 30 μg EE and 3 mg DRSP per tablet (brand names Yasmin, others) or 20 μg EE and 3 mg DRSP per tablet (brand names Yaz, Yasminelle, Nikki, others). [2] [3] A formulation with levomefolic acid (vitamin B 9) has also been marketed (brand names Beyaz, Safyral, others), with similar indications.
Each box, as supplied by the manufacturer, contains three blister packs of 28 tablets packaged in individual boxes. Each blister pack of 28 tablets contains 24 pink active pills containing drospirenone 3 mg, ethinylestradiol 20 mcg, and levomefolate calcium 0.451 mg and four light orange inactive pills containing levomefolate calcium 0.451 mg. [7] [9]
Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a combination of estradiol (E2), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used in menopausal hormone therapy, specifically the treatment of menopausal syndrome and osteoporosis, in postmenopausal women.
Estradiol 0.5 or 1 mg and drospirenone 0.25 or 0.5 mg ... 3 to 4 mg drospirenone is said to be equivalent to about 20 to 25 mg spironolactone in terms of ...
All contain an estrogen, ethinylestradiol or mestranol, [1] [2] in varying amounts, and one of a number of different progestogens. (Regarding the estrogen, the inactive 3-methyl ether of ethinylestradiol, which must be metabolized by the liver into the active ethinylestradiol; 50 μg of mestranol is equivalent to only 35 μg of ethinylestradiol and should not be used when high-dose [50 μg ...
Wrist-worn devices can predict imminent inflammatory and symptomatic inflammatory bowel disease flare-ups as far in advance as 7 weeks, a study suggests.
Ads
related to: drospirenone and ethinyl estradiol 3 mg/0.02mg